DSS, Inc. (DSS)
| Market Cap | 5.41M -56.7% |
| Revenue (ttm) | 18.45M -13.2% |
| Net Income | -27.39M |
| EPS | -2.90 |
| Shares Out | 10.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,955 |
| Open | 0.5810 |
| Previous Close | 0.5648 |
| Day's Range | 0.5221 - 0.5810 |
| 52-Week Range | 0.3605 - 1.8600 |
| Beta | 1.04 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About DSS
DSS, Inc. operates in the product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing businesses in the United States. The company manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products. It invests in or acquires companies in the biohealth and biomedical fields, including businesses that focuses on the advancement of drug discovery and prevention, inhibition, a... [Read more]
Financial Performance
In 2025, DSS, Inc.'s revenue was $20.76 million, an increase of 8.69% compared to the previous year's $19.10 million. Losses were -$23.93 million, -48.97% less than in 2024.
Financial StatementsNews
DSS, Inc. Proxy statement: Proxy filing
DSS, Inc. filed a proxy statement on October 20, 2026, providing details for shareholder voting and corporate governance matters.
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical's Proposed Business Combination with Zoar Limited
ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”) today announced that Zoar Limited (“Zoar” or “PubCo”) has filed a Registration Statement on ...
DSS, Inc. Launches DSS Robotics to Bring AI-Powered Automation to Enterprise Operations
New business will focus on practical robotics and intelligent automation solutions, with a planned Rochester innovation center for live deployments and customer demonstrations New business will focus ...
DSS announces decision not to proceed with proposed public offering.
DSS (DSS), Inc. “announced that after further consideration, the company determined not to proceed with its previously announced proposed public offering of Common Stock due to the limited capacity av...
DSS, Inc. Announces Decision Not to Proceed with Proposed Public Offering
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, com...
DSS announces launch of proposed public offering
DSS (DSS) announced that it has commenced a public offering to offer and sell shares of its Common Stock. Aegis Capital Corp. is acting as the sole book-running manager for…
DSS, Inc. Announces Launch of Proposed Public Offering
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial l...
DSS, Inc. Quarterly report: Q2 2026
DSS, Inc. has published its Q2 2026 quarterly earnings report on August 14, 2026.
DSS, Inc. Withdraws Registration Statement
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today announced that it has withdrawn its previously filed Registration Statement on Form S-1 with the U.S. Securities and Ex...
DSS, Inc. Quarterly report: Q1 2026
DSS, Inc. has published its Q1 2026 quarterly earnings report on May 15, 2026.
DSS reports ‘going concern’ audit opinion in 2025 10-K filing
DSS (DSS) announced that its annual report for the fiscal year ending December 31, 2025, filed on March 31, 2026, includes an audit opinion from HTL International LLC. that contains…
DSS, Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing
ROCHESTER, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced that its annual report (10-K) for the fiscal year ending December 31, 2025, filed on March 31, 2026, includes...
DSS, Inc. Registration statement: Registration filing
DSS, Inc. filed a registration statement on April 24, 2026, providing details about a securities offering with the SEC.
DSS, Inc. Registration statement: Registration filing
DSS, Inc. filed a registration statement on April 17, 2026, providing details about a securities offering with the SEC.
DSS, Inc. Annual report: Q4 2025
DSS, Inc. has published its Q4 2025 annual report on March 31, 2026.
DSS, Inc. Announces Closing of $1.0 Million Underwritten Public Offering
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, comm...
DSS prices 900,000 shares at $1.00 in underwritten public offering
DSS (DSS) announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $1M, before deducting underwriting fees and other offe...
DSS, Inc. Announces Pricing of $1.0 Million Underwritten Public Offering
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial le...
DSS, Inc. Quarterly report: Q3 2025
DSS, Inc. has published its Q3 2025 quarterly earnings report on November 14, 2025.
DSS, Inc. Proxy statement: Proxy Filing
DSS, Inc. filed a proxy statement on October 21, 2025, providing details for shareholder voting and corporate governance matters.
DSS, Inc. Proxy statement: Proxy Filing
DSS, Inc. filed a proxy statement on October 20, 2025, providing details for shareholder voting and corporate governance matters.
DSS, Inc. Quarterly report: Q2 2025
DSS, Inc. has published its Q2 2025 quarterly earnings report on August 14, 2025.
DSS’ Impact BioMedical announces strategic merger with Dr. Ashley’s
DSS (DSS) announced that its subsidiary, Impact BioMedical, has entered into a definitive merger agreement with Dr. Ashleys. Under the terms of the agreement, Dr. Ashleys will acquire Impact through…
DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating across diverse industries including packaging, real estate, and biomedical innovation, toda...
DSS, Inc. Quarterly report: Q1 2025
DSS, Inc. has published its Q1 2025 quarterly earnings report on May 15, 2025.